In the wave of precision medicine using peptide drugs, tetrapeptide PPKR (CAS No.103745-46-6) is becoming a focus of medical research and development due to its clear structural advantages and experimentally verified bioactivity. This linear tetrapeptide (H-Pro-Pro-Lys-Arg-OH) composed of proline-proline-lysine-arginine exhibits promising application prospects in anti-inflammatory and metabolic disease treatments due to its high purity and strong stability.
From a basic perspective, PPKR possesses core advantages for pharmaceutical-grade use: molecular formula C22H40N8O5, molecular weight 496.6, white powder appearance, excellent water solubility, and soluble in water or DMSO systems. Its purity, verified by HPLC, reaches over 98%, with some suppliers achieving mass production at 99% high purity. Stable supply is available from milligram-level samples to kilogram-level raw materials, strictly adhering to Chinese and international pharmacopoeia standards, providing a reliable material basis for medical research and development. Its unique amino acid composition endows it with dual potential: the cationic structure of lysine and arginine enhances biological targeting, while proline residues improve in vivo stability, laying the structural foundation for its physiological effects.
In medical applications, experimental data have preliminarily confirmed its core value. In the anti-inflammatory field, similar tetrapeptide studies have shown that synthetic peptides containing a proline-lysine structure can significantly inhibit the release of inflammatory factors—in a corneal epithelial cell inflammation model, pretreatment with this type of tetrapeptide reduced the level of the pro-inflammatory factor IL-6 from 52.45pg/ml to 38.08pg/ml, approaching normal levels (P.05), suggesting that PPKR may provide new treatment strategies for inflammation-related diseases such as dry eye through a similar mechanism. In the field of metabolic regulation, research on the neuropeptide family has shown that proline-containing peptides can induce satiety by activating hypothalamic receptors and may also regulate pancreatic β-cell function, providing potential targets for the treatment of obesity and diabetes. Furthermore, their cationic properties suggest antibacterial potential, potentially aiding in the fight against multidrug-resistant bacterial infections.
As a mature pharmaceutical intermediate, PPKR has achieved industrial-scale supply, supporting the entire process from basic research to pilot-scale production. With advancements in peptide synthesis technology, this tetrapeptide, possessing both structural advantages and bioactivity, is moving from the laboratory to clinical translation, opening new pathways for precision treatment in areas such as inflammatory diseases and metabolic disorders. In the future, further exploration of its mechanism of action and clinical applications is expected to make PPKR an important member of the peptide drug family.
